Analytical Data
-
Gene name
EREG
- Application
-
Alternative Names
EPR; ER; Proepiregulin
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14944
-
Expression Region
Val63~Leu108
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EREG (Epiregulin) is a member of the epidermal growth factor (EGF) family, which plays a crucial role in cellular processes such as proliferation, differentiation, and survival. It is expressed in various tissues and has been implicated in several physiological and pathological conditions, including cancer, wound healing, and inflammatory diseases. Recent studies emphasize the importance of EREG in tumor progression and metastasis, highlighting its potential as a therapeutic target. The research surrounding the EREG recombinant protein focuses on understanding its structure-function relationships, signaling pathways, and interactions with other growth factors and receptors. Additionally, the role of EREG in modulating the tumor microenvironment and its impact on immune responses are emerging areas of interest. Investigating the recombinant form of EREG not only aids in elucidating its biological functions but also facilitates the development of novel therapeutic strategies, such as monoclonal antibodies or inhibitors, to combat EREG-related pathologies. As we delve deeper into the mechanisms of EREG, its implications in oncology and regenerative medicine could lead to innovative approaches in treating various diseases, making it a significant target for future research and clinical applications.
